Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G SODIUM versus VEETIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G SODIUM versus VEETIDS.
PENICILLIN G SODIUM vs VEETIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment.
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic